

Douglas S Jones

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6442303/publications.pdf>

Version: 2024-02-01

12
papers

511
citations

840776

11
h-index

1199594

12
g-index

12
all docs

12
docs citations

12
times ranked

947
citing authors

#	ARTICLE	IF	CITATIONS
1	An engineered Axl 'decoy receptor' effectively silences the Gas6-Axl signaling axis. <i>Nature Chemical Biology</i> , 2014, 10, 977-983.	8.0	117
2	Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies. <i>Journal of Clinical Investigation</i> , 2016, 127, 183-198.	8.2	86
3	Profiling drugs for rheumatoid arthritis that inhibit synovial fibroblast activation. <i>Nature Chemical Biology</i> , 2017, 13, 38-45.	8.0	56
4	Engineering hepatocyte growth factor fragments with high stability and activity as Met receptor agonists and antagonists. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 13035-13040.	7.1	53
5	Developing therapeutic proteins by engineering ligand-receptor interactions. <i>Trends in Biotechnology</i> , 2008, 26, 498-505.	9.3	40
6	Functional Mutation of Multiple Solvent-Exposed Loops in the Ecballium elaterium Trypsin Inhibitor-II Cystine Knot Miniprotein. <i>PLoS ONE</i> , 2011, 6, e16112.	2.5	37
7	Structure-guided development of covalent TAK1 inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 838-846.	3.0	28
8	Inflammatory but not mitogenic contexts prime synovial fibroblasts for compensatory signaling responses to p38 inhibition. <i>Science Signaling</i> , 2018, 11, .	3.6	24
9	An engineered dimeric fragment of hepatocyte growth factor is a potent c-MET agonist. <i>FEBS Letters</i> , 2014, 588, 4831-4837.	2.8	23
10	Cell surface-tethered IL-12 repolarizes the tumor immune microenvironment to enhance the efficacy of adoptive T cell therapy. <i>Science Advances</i> , 2022, 8, eabi8075.	10.3	21
11	Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 1320-1328.	3.0	17
12	A participant-derived xenograft model of HIV enables long-term evaluation of autologous immunotherapies. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	9